In the published article, there was an error in Figure 4 as published. Antigen category of “Overexpressed Antigens” was mislabeled. The corrected Figure 4 and its caption appear below.
Figure 4
In the published article, there was also an error in Table 2 as published. Column heading of “%CD8+ of CD3+” was mislabeled and English decimal, “.” was not used. The corrected Table 2 and its caption appear below.
Table 2
| Patient # | CPI Modulation | TILs/Fragment (x10^6) | %CD4+ of CD3+ | %CD8+ of CD3+ | ICS Tumor Stimulation |
|---|---|---|---|---|---|
| MM 1 | Alone | 3.66 | 31.2 | 66.2 | Allogenic |
| Anti-CTLA-4 | 2.63 | 29.2 | 65.7 | ||
| Anti-PD-1 | 2.00 | 15.5 | 80.6 | ||
| MM 2 | Alone | 4.23 | 47.1 | 47.3 | Allogenic |
| Anti-CTLA-4 | 4.23 | 58.1 | 37.2 | ||
| Anti-PD-1 | 6.21 | 70.8 | 25.1 | ||
| MM 3 | Alone | 3.60 | 37.7 | 48.8 | Allogenic |
| Anti-CTLA-4 | 7.43 | 26.7 | 63.2 | ||
| Anti-PD-1 | 3.93 | 31.0 | 24.4 | ||
| MM 4 | Alone | 0.50 | 27.5 | 69.3 | Allogenic |
| Anti-CTLA-4 | 0.74 | 39.4 | 56.1 | ||
| Anti-PD-1 | 8.00 | 7.40 | 91.0 | ||
| MM 5 | Alone | 5.18 | 52.0 | 40.7 | Autologous |
| Anti-CTLA-4 | 2.78 | 87.2 | 10.8 | ||
| Anti-PD-1 | 3.65 | 61.6 | 35.1 | ||
| MM 6 | Alone | 5.14 | 87.9 | 11.1 | Allogenic |
| Anti-CTLA-4 | 2.60 | 7.90 | 83.7 | ||
| Anti-PD-1 | 4.30 | 48.6 | 49.3 | ||
| MM 7 | Alone | 0.23 | 48.1 | 47.4 | Allogenic |
| Anti-CTLA-4 | 0.09 | 46.0 | 44.9 | ||
| Anti-PD-1 | 0.95 | 22.6 | 68.4 | ||
| MM 8 | Alone | 4.15 | 21.6 | 75.6 | Allogenic |
| Anti-CTLA-4 | 2,73 | 72.9 | 24.9 | ||
| Anti-PD-1 | 4.35 | 26.8 | 69.9 | ||
| MM 9 | Alone | 5.25 | 18.7 | 79.6 | Autologous |
| Anti-CTLA-4 | 2.55 | 11.8 | 84.9 | ||
| Anti-PD-1 | 2.70 | 33.2 | 63.0 | ||
| MM 10 | Alone | 5.16 | 8.90 | 89.7 | Autologous |
| Anti-CTLA-4 | 6.01 | 12.7 | 85.9 | ||
| Anti-PD-1 | 6.23 | 11.0 | 87.4 | ||
| MM 11 | Alone | 11.18 | 69.1 | 29.3 | Autologous |
| Anti-CTLA-4 | 1.78 | 35.3 | 56.0 | ||
| Anti-PD-1 | 16.2 | 2.00 | 97.1 | ||
| MM 12 | Alone | 1.76 | 28.0 | 68.0 | Autologous |
| Anti-CTLA-4 | 3.44 | 9.80 | 83.0 | ||
| Anti-PD-1 | 5.41 | 17.2 | 77.5 | ||
| MM 13 | Alone | 0.03 | 57.2 | 33.2 | n.d. |
| Anti-CTLA-4 | 0.30 | 23.8 | 69.3 | ||
| Anti-PD-1 | 17.43 | 6.70 | 91.9 | ||
| MM 14 | Alone | 2.98 | 39.2 | 59.2 | Allogenic |
| Anti-CTLA-4 | 2.69 | 50.5 | 43.6 | ||
| Anti-PD-1 | 6.94 | 78.2 | 19.1 | ||
| MM 15 | Alone | n.d. | n.d. | n.d. | n.d. |
| Anti-CTLA-4 | n.d. | n.d. | n.d. | ||
| Anti-PD-1 | n.d. | n.d. | n.d. |
Sample overview including TILs/fragment, CD4 and CD8 frequencies, and ICS tumor stimulation for the three TME conditions.
Red text indicates culture not established. N.d. indicates no data due to lack of TIL production.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
tumor-infiltrating lymphocyte (TIL), checkpoint inhibition, metastatic melanoma, cancer immunotherapy, tumor microenevironment, adoptive cell immunotherapy, DNA Barcoding
Citation
Hulen TM, Friese C, Kristensen NP, Granhøj JS, Borch TH, Peeters MJW, Donia M, Andersen MH, Hadrup SR, Svane IM and Met Ö (2024) Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes. Front. Immunol. 15:1462081. doi: 10.3389/fimmu.2024.1462081
Received
09 July 2024
Accepted
10 July 2024
Published
18 July 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
15 - 2024
Updates
Copyright
© 2024 Hulen, Friese, Kristensen, Granhøj, Borch, Peeters, Donia, Andersen, Hadrup, Svane and Met.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Thomas Morgan Hulen, thomas.morgan.hulen@regionh.dk; Özcan Met, ozcan.met@regionh.dk
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.